歌禮製藥(01672.HK)治療非酒精性脂肪性肝炎藥物完成美國I期臨床試驗
歌禮製藥(01672.HK)公布,其全資附屬甘萊完成在研管線藥物ASC43F美國I期臨床試驗。ASC43F是公司完全自主研發的雙靶點固定劑量複方製劑(FDC),用於治療非酒精性脂肪性肝炎(NASH)。
ASC43F在健康受試者中具有良好的安全性和耐受性,未出現具有臨床意義的藥物相關不良事件。來源於SC43F片的ASC41和ASC42的藥代動力學參數,與ASC41和ASC42單藥治療的藥代動力學參數具有一致性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.